Lexeo Therapeutics, Inc. Common Stock (LXEO) financials · $147.7M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Lexeo Therapeutics, Inc. Common Stock (LXEO) $147.7M cap.
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Operating Income | −$109.26M | −$105.77M | |
| Net Income | −$99.96M | −$98.33M | |
| EPS (Diluted) | −$1.86 | −$3.09 | |
| Unlock 5 years of statements: Lician Pro $149/yr | |||
| Line | FY2025 | FY2024 | Pro (3 older periods with Lician Pro) |
|---|---|---|---|
| Total Assets | $268.69M | $146.94M | |
| Current Assets | $188.39M | $126.12M | |
| Cash & Equivalents | $63.00M | $35.01M | |
| PP&E | $1.14M | $1.03M | |
| Total Liabilities | $22.02M | $30.10M | |
| Current Liabilities | $16.81M | $22.85M | |
| Shareholders' Equity | $246.67M | $116.84M | |
| Retained Earnings | −$380.13M | −$280.17M |
| Line | FY2025 | FY2024 | Pro (2 older periods with Lician Pro) |
|---|---|---|---|
| Operating Cash Flow | −$98.56M | −$81.15M | |
| CapEx | $397.00K | $481.00K | |
| Investing Cash Flow | −$90.25M | −$94.08M | |
| Financing Cash Flow | $216.79M | $88.78M | |
| Net Change in Cash | $27.98M | −$86.45M | |
| Free Cash Flow | −$98.96M | −$81.63M |
Source: Company filings with the SEC (EDGAR) · Latest period FY2025
FAQ
What is LXEO P/E and revenue?
Lexeo Therapeutics, Inc. Common Stock (LXEO) $147.7M cap.
What is LXEO revenue?
LXEO income-statement cache has no revenue figure yet.
Is LXEO profitable?
Lexeo Therapeutics, Inc. Common Stock last cached net income is -$100.0M (FY2025).
What are LXEO total assets?
Lexeo Therapeutics, Inc. Common Stock last cached total assets are $268.7M (FY2025).
What is LXEO free cash flow?
Lexeo Therapeutics, Inc. Common Stock last cached free cash flow is -$99.0M (FY2025).
Not investment advice. Figures as reported in company filings, not a live feed.